2009 – Dr. Felder develops the theories that make the Felder Doctrine. Patents written and submitted
December 2010 – PBI incorporated in Nevada
December 2010 – Assembled Board of Directors. includes the Doctor, two attorneys, and individuals previously holding officer positions for public companies.
January 2011 – Halberd Corporation, Inc. begins process of “going public”.
March 2012 – Dr. Mitchell Felder meets with Dr. Robert A. Kirken, Ph.D. Professor and Chair, Department of Biological Sciences at the University of Texas at El Paso (UTEP).
April 2012 – UTEP demonstrates data to support Proof of Concept: Selective Depletion of Small Reactive Molecules.
May 2012 – PBI and UTEP sign Collaborative Agreement: Aphaeresis Selective Depletion of Small Reactive Molecules and Pathogens that Involves a Novel Treatment of Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic, Lateral Sclerosis (ALS or Lou Gehrig’s disease), Blood Sepsis, Cancer, Heart Attacks and Strokes.
June 2012 – UTEP presents Scope of Work Agreement for the Pre-clinical Development of Halberd Corporation Therapeutic Strategies
July 2012 – PBI and UTEP sign Scope of Work Agreement. Halberd Corporation, Inc. receives a letter of intent from William Beaumont Army Medical Center (WBAMC) stating their desire to join the consortium with their primary expertise in animal and clinical testing
August 2012 – Mutual Non-Disclosure Agreement with UTEP, PBI, and US Army Clinical Investigation Regulatory Office (CIRO). Halberd Corporation, Inc. begins primary fundraising for laboratory development and clinical testing–targeting private consortiums, institutional funds, grants, strategic partnerships, and philanthropic donations. HALB opens on OTCBB at $1.01.